VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KWAMME ANDERSON | — |
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Medicare/Medicaid MMM
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KWAMME ANDERSON | — |
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."
| Lobbyist | Covered position, as disclosed |
|---|---|
| KWAMME ANDERSON | — |
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Budget/Appropriations BUD
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
| Lobbyist | Covered position, as disclosed |
|---|---|
| KWAMME ANDERSON | — |
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Medical/Disease Research/Clinical Labs MED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
| Lobbyist | Covered position, as disclosed |
|---|---|
| KWAMME ANDERSON | — |
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.